Company

Lepu Medical's Minwei Biotech Secures NMPA Clinical Trial Approval for MWX205 – World's First PCSK9/ANGPTL3 Dual‑Target siRNA for Dyslipidemia
Lepu Medical TechnologySHE: 300003

Lepu Medical’s Minwei Biotech Secures NMPA Clinical Trial Approval for MWX205 – World’s First PCSK9/ANGPTL3 Dual‑Target siRNA for Dyslipidemia

Lepu Medical Technology (Beijing) Co., Ltd. (SHE: 300003) announced that MWX205 Injection, a dual‑target small interfering RNA (siRNA) drug independently developed by its controlled subsidiary Shanghai Minwei Biotechnology Co., Ltd.…

IASO Bio's In Vivo CAR‑T IASO208 Clears NMPA IND – CD20‑Targeting Therapy Heads to Phase Ib in the US for R/R B‑NHL

IASO Bio’s In Vivo CAR‑T IASO208 Clears NMPA IND – CD20‑Targeting Therapy Heads to Phase Ib in the US for R/R B‑NHL

AstraZeneca Acquires Omniose – Vaccine Bioconjugation Specialist Bolsters Bacterial Threat Defense Within Infectious Disease Unit

AstraZeneca Acquires Omniose – Vaccine Bioconjugation Specialist Bolsters Bacterial Threat Defense Within Infectious Disease Unit

Empowering Chinese Pharma’s Global Expansion

Leverage premier media reach to connect your pipeline with global partners. Contact us to drive your international growth today.
Contact US
Zai Lab Secures Rights to Vertex's Povetacicept in Key Asian Markets
HKG: 9688NASDAQ: ZLAB

Zai Lab Secures Rights to Vertex’s Povetacicept in Key Asian Markets

Eli Lilly in Advanced Talks to Acquire Scorpion Therapeutics for $2.5 Billion
Eli LillyNYSE: LLY

Eli Lilly in Advanced Talks to Acquire Scorpion Therapeutics for $2.5 Billion

Light Horse Therapeutics Partners with Novartis in First-in-Class Drug Development
Light Horse TherapeuticsNovartis

Light Horse Therapeutics Partners with Novartis in First-in-Class Drug Development

Samsung Bioepis and Teva Partner on Biosimilar EPYLLI for US Market
BiosimilarsNASDAQ: AZN

Samsung Bioepis and Teva Partner on Biosimilar EPYLLI for US Market

Show More